SLDB Stock Catalyst: Solid Biosciences Announces Pricing of Underwritten Offering and Positive Clinical Data

Solid Biosciences Inc. announced on 2025-02-18 Solid Biosciences announced the pricing of an underwritten offering of its common stock and reported positive initial clinical data from its next-generation Duchenne gene therapy candidate SGT-003.

The announcement cited 35,739,810 shares, $4.03 per share, 13,888,340 shares, $4.029 per pre-funded warrant, $200.0 million, 110%, 135%, 112%, and 84%. Share consideration (payable in the issuer's shares): 35,739,810.

Solid Biosciences Inc. has a free float of 40,407,400 shares and 77,910,000 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.